An observational study in Infertility, Female and Infertility, Male, sponsored by Genomic Prediction Inc.. Not yet recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Genomic Prediction Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Infertility, Female with a site in United States — 22 open to participants now, 24 under way, none of them phase 3. Infertility, Female · United States.
Among the 65 studies in Infertility, Female with a site in United States, this one is the 8th largest by planned enrollment of the 18 observational ones that give a count, is one of 4 that started in 2026, is one of 18 observational ones, reaches primary completion later than 14 of the 23 other live ones, and was the 34th registered.
553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.
Browse Infertility, Female studies →22 of the 65 studies in Infertility, Female with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–40 · Women only
Shady Grove Fertility Reproductive Science Center · Sites in United States
Women only
University of Southern California · Sites in United States
Ages 18–44 · Women only
University of Colorado, Denver · Sites in United States
Ages 18–38 · Women only · Healthy volunteers
Center for Reproductive Health & Gynecology · Sites in United States, Mexico
Ages 18–55 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 4 · Phase 4 6
First in 2004; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 160 across 163 observational studies indexed under Infertility, Female.
Median enrollment 50 across the 47 interventional studies, 175 across the 18 observational. Of the 33 that completed or were terminated, 7 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 65 have an industry lead sponsor. The 10 most frequent:
Genomic Prediction Inc. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Genomic Prediction Inc. has 3 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
5 of the studies in Infertility, Female with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06434233Johns Hopkins UniversityOpioid Use After Laparoscopic Salpingectomy | 2026-11 |
| NCT05997407Virginia Polytechnic Institute and State UniversityThe Effect of a Mindset Management Approach on Stress Levels in Women With Infertility | 2026-12 |
| NCT07858435New Hope Fertility CenterIntra-ovarian CAPA-IVM vs Standard IVM | 2027-03 |
| NCT06686537University of Colorado, DenverConvergent Mechanisms Underlying Reprometabolic Syndrome in Women | 2027-10 |
| NCT04628507Genomic Prediction Inc.Cell Free Preimplantation Genetic Testing | 2027-11-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 65 studies in Infertility, Female with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to develop preimplantation genetic testing methods from embryo culture media (cell free). Genetic testing of culture media will be compared to conventional methods based on embryo biopsies.
Consenting patients will receive standard clinical IVF and PGT. Culture media from embryos will be collected for analysis. Collection of media will include laser assisted collapse of the blastocyst on day 5, 6, or 7 in order to release blastocoel fluid into the culture media. Embryos diagnosed as aneuploid or monogenic disorder affected (abnormal embryos) will be donated for additional analysis with patient consent.
Results obtained from culture media will not be provided to the patients. The information obtained from cf-PGT will be compared to results obtained from embryo biopsies obtained as part of routine PGT and evaluated for concordance and reliability. Abnormal embryos will be rebiopsied (\~3 to 4 times) to evaluate concordance with cf-PGT and the original clinical trophectoderm biopsy PGT results.
All cases will be labelled using a 5-digit barcode and embryo number or saliva source code. Because PGT will be conducted under clinical regulatory approval (CAP and CLIA), patient information will be protected under HIPAA guidelines, including sending reports in encrypted secure email per standard operating procedures. All publications and presentations will maintain de-identification of any patient data used.
Patients may withdraw from the study at any time by contacting the principal investigator of their respective recruiting site. They will continue to receive standard of care through their treating IVF center. A recruitment target of 200 patients is intended for this study.
Patients undergoing IVF electing to utilize LifeView testing who consented for embryo spent media collection and analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Spent media collection
Embryo spent culture media, otherwise discarded as per standard of care, is collected once embryos have completed in vitro culture.
Concordance with PGT
Concordance rates with PGT diagnosis from trophectoderm biopsies
Time frame: 14 dyas
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Nov 2027, 17 months later.
Of 88 observational studies under Infertility, Female, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 69. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genomic Prediction Inc.